0001562180-23-001424.txt : 20230215
0001562180-23-001424.hdr.sgml : 20230215
20230215164648
ACCESSION NUMBER: 0001562180-23-001424
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230213
FILED AS OF DATE: 20230215
DATE AS OF CHANGE: 20230215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Benecchi Christopher
CENTRAL INDEX KEY: 0001881403
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 23636014
MAIL ADDRESS:
STREET 1: C/O SAGE THERAPEUTICS, INC.
STREET 2: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-02-13
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001881403
Benecchi Christopher
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
false
true
false
false
Chief Business Officer
Stock Option (Right to Buy)
45.28
2023-02-13
4
A
false
20900.00
0.00
A
2033-02-13
Common Stock
20900.00
20900.00
D
The securities awarded on February 13, 2023 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,225 shares of common stock shall vest on the one year anniversary of February 13, 2023, with 15,675 shares vesting in 36 equal monthly installments thereafter.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Christopher Benecchi
2023-02-15
EX-24
2
cbenecchipoa.txt
POA
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer)
and Jennifer Fitzpatrick (VP, Corporate Counsel), for as long as they
remain employees of Sage Therapeutics, Inc., and Stuart Falber of
WilmerHale, each acting singly, or their successors in role, to take
the following actions, acting as my agent and attorney-in-fact, with
full power of substitution:
(1) to prepare and sign on my behalf any Form 4 or Form 5
pursuant to Section 16 of the Securities Exchange Act of 1934, as
amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am a director or
executive officer of Sage Therapeutics, Inc., and shall not be
affected by my subsequent disability or incompetence. I may revoke
this Power of Attorney by written notice delivered, in person or by
nationally recognized courier, to the attention of the SVP, General
Counsel of Sage Therapeutics, Inc.
/s/ Christopher Benecchi
Name: Christopher Benecchi
Date: September 13, 2021
P (617) 299-8380 . F (617) 299-8379 . 215 First Street, Cambridge, MA 02142